Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANA001 in Moderate and Severe COVID-19
NCT04603924Phase 3Completed
- Sponsor
- NeuroBo Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ANA001 with Matching Placebo (2 arms). Primary endpoints: Number of Subjects Experiencing Treatment-Emergent Adverse Events at Day 60 and Number of Subjects Experiencing Treatment-Emergent Serious Adverse Events at Day 60. Started Oct 2020; status: completed.
02
Drugs
ANA001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04603924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603924.